Propylisopropyltryptamine

Summary

Propylisopropyltryptamine (PiPT) is a chemical in the tryptamine family, which reportedly produces psychedelic and hallucinogenic effects that resemble those of other related dialkyl tryptamine derivatives,[1] although PiPT is reportedly relatively weak and short lasting. It has been sold as a designer drug, first being identified in 2021 in British Columbia, Canada.[2]

Propylisopropyltryptamine
Clinical data
ATC code
  • none
Identifiers
  • [2-(1H-indol-3-yl)ethyl]-N-propyl-N-isopropylamine
CAS Number
  • 1354632-00-0 ☒N
PubChem CID
  • 57464898
ChemSpider
  • 21106369 checkY
UNII
  • Q2Y9D5Q4T4
CompTox Dashboard (EPA)
  • DTXSID20726699 Edit this at Wikidata
Chemical and physical data
FormulaC16H24N2
Molar mass244.382 g·mol−1
3D model (JSmol)
  • Interactive image
  • CC(C)N(CCC)CCc2c[nH]c1ccccc12
  • InChI=1S/C16H24N2/c1-4-10-18(13(2)3)11-9-14-12-17-16-8-6-5-7-15(14)16/h5-8,12-13,17H,4,9-11H2,1-3H3 checkY
  • Key:OFXPLOPRCQJJFP-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Chemistry edit

PiPT is short for N-propyl-N-isopropyl-tryptamine. PiPT is a tryptamine, which all belong to a larger family of compounds known as indolethylamines. PiPT is closely related to the compounds DPT and DiPT.

Dosage edit

PiPT is reported as being active at doses of 50-100mg orally, or 25mg smoked.[citation needed]

Effects edit

Very little is known about the psychopharmacological properties of PiPT, but reports suggest it produces psychedelic effects similar to those of other hallucinogenic tryptamine derivatives, that can last around 2-4 hours.[citation needed]

Dangers edit

There have been no reported deaths or hospitalizations from PiPT, but its safety profile is unknown.[citation needed]

Legality edit

PiPT is unscheduled and uncontrolled in the United States, but possession and sales of PiPT could be prosecuted under the Federal Analog Act because of its structural similarities to other hallucinogenic tryptamine derivatives.

See also edit

References edit

  1. ^ Catalani V, Corkery JM, Guirguis A, Napoletano F, Arillotta D, Zangani C, Vento A, Schifano F (August 2021). "Psychonauts' psychedelics: A systematic, multilingual, web-crawling exercise". European Neuropsychopharmacology. 49: 69–92. doi:10.1016/j.euroneuro.2021.03.006. hdl:2299/24309. PMID 33857740. S2CID 233206904.
  2. ^ Knill A, Tobias S, Matthews J, Ti L (June 2022). A Report on British Columbia’s Unregulated Drug Supply. Drug checking trends across British Columbia, January to December 2021 (PDF). British Columbia Centre on Substance Use (Report).

External links edit